“Our due diligence revealed that while Zadaxin promises much, reputable studies indicate it delivers little if any benefit to patients. In theory, Zadaxin should improve the effect of pegylated interferon alpha, Roche's leading drug for Hepatitis treatment, and is also touted as being effective when used in conjunction with other drugs to aid the healing process by boosting the immune system. Zadaxin is essentially considered a vaccine enhancer. In practice, Zadaxin has failed multiple Phase III FDA studies for various indications of effect. It should therefore come as no surprise that SCLN has not been able to win approval for sale of Zadaxin in the U.S. Furthermore, Zadaxin is not approved for sale in Europe. These circumstances exist despite a 10+ year marketing/distribution collaboration with and $3.7 million funding from Italian distributor Sigma-Tau.”

http://seekingalpha.com/article/713951-sciclone-s-strategic-partner-selling-out-sec-doj-and-competitors-closing-in